Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

NCT03451422 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Efavaleukin Alfa
DRUG: Placebo

Sponsor

Amgen